CA
CTIC

Calton & Associates’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Calton & Associates’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed – – 1520
2017
Q4 		$0 Buy
+10
New +$29 ﹤0.01% 1549

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Calton & Associates's CTIC Position: Q1 2018 in Review

Calton & Associates sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2018, closing a stake of 10 shares.

Calton & Associates first reported a position in CTIC in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2018.

  • Calton & Associates reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 10 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2018.
  • Calton & Associates first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q4 2017.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.